Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.

Mohammadi S, Hosseinzadeh-Attar MJ, Hosseinnezhad A, Hosseini SH, Eshraghian MR, Nezhad MK, Rahmani M, Karimi M.

Diabetes Metab Syndr. 2011 Apr-Jun;5(2):71-5. doi: 10.1016/j.dsx.2012.02.014.

PMID:
22813406
2.

Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: a contradictory piece of the puzzle.

de Luis DA, Sagrado MG, Aller R, Conde R, Izaola O.

Nutrition. 2010 Nov-Dec;26(11-12):1130-3. doi: 10.1016/j.nut.2008.11.019.

PMID:
19211226
3.

Association of adiponectin with dietary factors and cardiovascular risk factors in type 2 diabetes mellitus patients.

Attar MJ, Mohammadi S, Karimi M, Hosseinnezhad A, Hosseini SH, Eshraghian MR, Jafari N, Rahmani M, Karimi F, Nezhad MK.

Diabetes Metab Syndr. 2013 Jan-Mar;7(1):3-7. doi: 10.1016/j.dsx.2013.02.027.

PMID:
23517787
4.

Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients.

Mirzaei K, Hossein-Nezhad A, Javad Hosseinzadeh-Attar M, Jafari N, Najmafshar A, Mohammadzadeh N, Larijani B.

Minerva Endocrinol. 2009 Dec;34(4):273-9.

PMID:
20046156
5.

[Association between both resistin, visfatin and insulin resistance as well as β cell function in the first-degree relatives of type 2 diabetes mellitus].

Zhang XJ, Wang Z, Li HH, Yu L, Gao S.

Zhonghua Liu Xing Bing Xue Za Zhi. 2010 Dec;31(12):1393-6. Chinese.

PMID:
21223671
7.

Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.

Pfützner A, Marx N, Walcher D, Löbig M, Seidel D, Forst T.

Clin Lab. 2008;54(7-8):237-41.

PMID:
18942491
8.

Apelin, vaspin, visfatin and adiponectin in large for gestational age infants with insulin resistance.

Cekmez F, Canpolat FE, Pirgon O, Çetinkaya M, Aydinoz S, Suleymanoglu S, Ipcioglu OM, Sarici SU.

Cytokine. 2011 Nov;56(2):387-91. doi: 10.1016/j.cyto.2011.06.007.

PMID:
21742512
9.

Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters.

Caixàs A, Tirado R, Vendrell J, Gallart L, Megía A, Simón I, Llauradó G, González-Clemente JM, Giménez-Palop O.

Clin Endocrinol (Oxf). 2009 Nov;71(5):733-8. doi: 10.1111/j.1365-2265.2009.03546.x.

PMID:
19222486
10.

The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.

Erdem G, Dogru T, Tasci I, Bozoglu E, Muhsiroglu O, Tapan S, Ercin CN, Sonmez A.

Diabetes Res Clin Pract. 2008 Nov;82(2):214-8. doi: 10.1016/j.diabres.2008.07.021.

PMID:
18778865
11.

Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.

Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N.

Exp Clin Endocrinol Diabetes. 2011 Feb;119(2):63-8. doi: 10.1055/s-0030-1265174.

PMID:
21031343
12.

Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review.

Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ.

Diabetes Metab Res Rev. 2011 Sep;27(6):515-27. doi: 10.1002/dmrr.1201. Review.

PMID:
21484978
13.

The role of leptin, soluble leptin receptor, adiponectin and visfatin in insulin sensitivity in preterm born children in prepubertal ages.

Yanni D, Darendeliler F, Bas F, Kucukemre Aydin B, Coban A, Ince Z.

Cytokine. 2013 Oct;64(1):448-53. doi: 10.1016/j.cyto.2013.04.034.

PMID:
23726672
14.

Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis.

Niepolski L, Grzegorzewska AE, Młot-Michalska M.

Int Urol Nephrol. 2010 Jun;42(2):441-52. doi: 10.1007/s11255-009-9525-1.

PMID:
19184512
15.

Adiponectin and visfatin levels in extremely low birth weight infants; they are also at risk for insulin resistance.

Cekmez F, Canpolat FE, Pirgon O, Aydemir G, Tanju IA, Genc FA, Tunc T, Aydinöz S, Yildirim S, Ipcioglu OM, Sarici SU.

Eur Rev Med Pharmacol Sci. 2013 Feb;17(4):501-6.

16.

Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes.

Zhu J, Schott M, Liu R, Liu C, Shen B, Wang Q, Mao X, Xu K, Wu X, Schinner S, Papewalis C, Scherbaum WA, Liu C.

Horm Metab Res. 2008 Nov;40(11):801-5. doi: 10.1055/s-0028-1082040.

PMID:
18686225
17.

Adiponectin and E-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease(s).

El-Mesallamy HO, Hamdy NM, Salman TM, Mahmoud S.

Minerva Endocrinol. 2011 Sep;36(3):163-70.

PMID:
22019747
18.

Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.

Esteghamati A, Alamdari A, Zandieh A, Elahi S, Khalilzadeh O, Nakhjavani M, Meysamie A.

Diabetes Res Clin Pract. 2011 Feb;91(2):154-8. doi: 10.1016/j.diabres.2010.11.003.

PMID:
21122936
19.

Serum visfatin concentration and endothelial dysfunction in chronic kidney disease.

Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Cakir E, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J.

Nephrol Dial Transplant. 2008 Mar;23(3):959-65.

PMID:
17984105
20.

Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.

Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S, Ozgurtas T, Bingol S.

Diabetes Res Clin Pract. 2007 Apr;76(1):24-9.

PMID:
16956691

Supplemental Content

Support Center